Clinical Trials
2 trialsNCT04409860 2023-04-11
CQGOG0102
Chongqing University Cancer Hospital
Phase NA Recruiting
NCT03220009 2018-10-03
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
National Cancer Institute (NCI)
Phase 2 Withdrawn